Skip to main content
Premium Trial:

Request an Annual Quote

Unsolicited Bid Causes Applied Imaging to Raise Price Genetix Must Pay for It

NEW YORK (GenomeWeb News) — Applied Imaging today said that an unsolicited bid from a third party to acquire all of its outstanding shares has caused it to the raise by around 24 percent the original price that suitor Genetix will pay to acquire it.
Genetix will now pay around $22.7 million for Applied Imaging after the companies amended the terms of the acquisition on Nov. 2 following the unsolicited bid.
As GenomeWeb News reported in September, Genetix said it would acquire Applied Imaging for $18.3 million in cash, or $3.06 per share. At the time the companies said the deal would close in the fourth quarter
Yesterday’s amendment increased from $3.70 per share to $3.80 the amount Genetix will pay for Applied Imaging's stockholders per share.
The firms said they expect to meet on Nov. 21 to approve the proposed acquisition.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.